Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Bitcoin

Bitcoin Strategy Firm Poised for Historic S&P 500 Inclusion

Robert Sasse by Robert Sasse
September 2, 2025
in Bitcoin, Blockchain, Crypto Stocks, S&P 500
0
Strategy Stock
0
SHARES
283
VIEWS
Share on FacebookShare on Twitter

A pivotal moment for digital asset adoption may arrive this Friday as Strategy Inc., the company formerly known as software provider MicroStrategy, awaits a landmark decision. The firm could become the first corporate Bitcoin treasury holder to join the prestigious S&P 500 index, an event analysts predict would permanently reshape the financial landscape.

Unprecedented Profits Fuel Qualification

The company’s controversial strategy has transitioned from what many perceived as a speculative gamble to a resounding financial success. For Q2 2025, Strategy reported an operating income of $14 billion and a net profit of $10 billion. This remarkable performance stems primarily from updated accounting standards implemented in January, which now permit the recognition of unrealized gains from its massive Bitcoin holdings.

Strategy has amassed 597,325 Bitcoin, currently valued at approximately $65 billion, making it the world’s largest corporate holder of the cryptocurrency. When Bitcoin’s price surged beyond $100,000 during the quarter, these holdings generated enormous paper profits.

While the company’s legacy software subscription business demonstrated strong growth of nearly 70%, its overall revenue increase was more modest. Total revenues reached $114.5 million, representing growth of 2.7%.

Should investors sell immediately? Or is it worth buying Strategy?

Meeting All Index Requirements

Market analysts confirm Strategy now satisfies every criterion for S&P 500 inclusion. The company maintains its US exchange listing, commands a market capitalization well above the $8.2 billion minimum threshold, demonstrates sufficient trading volume, and reports positive earnings. With a current valuation of around $107.5 billion, the firm comfortably ranks among potential index candidates.

Company leadership has projected full-year 2025 operating income could reach $34 billion, though this forecast depends significantly on their assumption that Bitcoin will trade at $150,000 by year’s end.

Implications of Friday’s Decision

Inclusion in the benchmark index would trigger substantial investment flows from index-tracking funds, firmly establishing Strategy within the traditional financial establishment. Market experts currently identify potential upside, with average price targets reaching $567 per share.

The true significance extends far beyond a single company’s achievement. This would mark the first time a enterprise built primarily around a Bitcoin strategy gains entry into America’s most important equity index. What began as a contentious corporate experiment may culminate in a watershed moment for digital asset acceptance across global finance.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from March 25 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Technology Select Sector SPDR® Fund Stock
AI & Quantum Computing

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

March 25, 2026
Coinbase Stock
Analysis

Regulatory Proposal Sparks Sell-Off in Coinbase Shares

March 25, 2026
SPDR® S&P® U.S. Dividend Aristocrats UCITS ETF (Dist) Stock
Dividends

A Quarterly Review of the SPDR S&P U.S. Dividend Aristocrats ETF

March 24, 2026
Next Post
Eli Lilly Stock

Eli Lilly's Oral Weight-Loss Drug Poised to Reshape Market Dynamics

Coinbase Stock

Coinbase Targets Australia's $2.8 Trillion Pension Sector with New Crypto Offering

Iovance Stock

Iovance Faces Pivotal Investor Events Following Equity Offering

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com